Online inquiry

IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ387MR)

This product GTTS-WQ387MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TYRP1 gene. The antibody can be applied in Malignant melanoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000550.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7306
UniProt ID P17643
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ387MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4924MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ14330MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ1974MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ14267MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG7155
GTTS-WQ13219MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ15130MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ1737MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ15469MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-0107
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW